April 28, 2017
Recommended Topic Related To:


"The U.S. Food and Drug Administration today allowed marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old. When used as part of "...



Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)


Because of its association with life threatening hepatic failure, CYLERT (pemoline) should not ordinarily be considered as first line drug therapy for ADHD (see INDICATIONS AND USAGE).

Since CYLERT (pemoline) ´s marketing in 1975, 13 cases of acute hepatic failure have been reported to the FDA. While the absolute number of reported cases is not large, the rate of reporting ranges from 4 to 17 times the rate expected in the general population. This estimate may be conservative because of under reporting and because the long latency between initiation of CYLERT (pemoline) treatment and the occurrence of hepatic failure may limit recognition of the association. If only a por-tion of actual cases were recognized and reported, the risk could be substantially higher.

Of the 13 cases reported as of May 1996, 11 resulted in death or liver transplantation, usually within four weeks of the onset of signs and symptoms of liver failure. The ear-liest onset of hepatic abnormalities occurred six months after initiation of CYLERT (pemoline) . Although some reports described dark urine and nonspecific prodromal symptoms (e.g., anorexia, malaise, and gastrointestinal symp-toms), in other reports it was not clear if any prodromal symptoms preceded the onset of jaundice. It is also not clear if the recom-mended baseline and periodic liver function testing are predictive of these instances of acute liver failure. CYLERT (pemoline) should be dis-continued if clinically significant hepatic dysfunction is observed during its use (see PRECAUTIONS).


CYLERT (pemoline) is a central nervous system stimulant. Pemoline is structurally dissimilar to the amphetamines and methylphenidate.

It is an oxazolidine compound and is chemically identified as 2-amino-S-phenyl-2-oxazolin4-one.

Pemoline is a white, tasteless, odorless powder, relatively insoluble (less than 1 mg/mL) in water, chloroform, ether, acetone, and benzene; its solubility in 95% ethyl alcohol is 2.2 mg/mL.

CYLERT (pemoline) is supplied as tablets containing 18.75 mg, 37.5 mg or 75 mg of pemoline for oral administration. CYLERT (pemoline) is also available as chewable tablets containing 37.5 mg of pemoline.

Inactive Ingredients

18.75 mg tablet: corn starch, gelatin, lactose, magnesium hydroxide, polyethylene glycol and talc.

37.5 mg tablet: corn starch, FD& C Yellow No. 6. gelatin, lactose, magnesium hydroxide, polyethylene glycol and talc.

37.5 mg chewable tablet: corn starch FD& C Yellow No. 6, magnesium hydroxide, magnesium stearate, mannitol, Polyethylene glycol, povidone, talc and artificial flavor.

75 mg tablet: corn starch, gelatin, iron oxide, lactose, magnesium hydroxide, polyethylene glycol and talc.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.